Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701682 | 0.87 | HRH3 (0.45) | OPRM1OPRL1KCNH2LMNACXCR4 | |
| SCHEMBL15701683 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1HTR2AHRH1HTR2C | |
| SCHEMBL15701689 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1HTR2AHRH1HTR2C | |
| SCHEMBL15701681 | 0.83 | OPRM1 (0.41) | OPRM1OPRL1KCNH2CXCR4 | |
| SCHEMBL14149843 | 0.82 | OPRM1 (0.60) | OPRM1OPRL1HTR2AHRH1HTR2C | |
| SCHEMBL15703786 | 0.82 | OPRM1 (0.60) | OPRM1OPRL1HTR2AHRH1HTR2C | |
| SCHEMBL15701686 | 0.82 | OPRM1 (0.43) | OPRM1OPRL1HTR2AHRH1HTR2C | |
| SCHEMBL13587827 | 0.76 | CXCR4 (0.41) | OPRM1OPRL1KCNH2ALDH1A1CXCR4 | |
| SCHEMBL14558528 | 0.75 | CXCR4 (0.40) | OPRM1KCNH2BCL2CXCR4MEN1 | |
| SCHEMBL7309721 | 0.75 | CXCR4 (0.40) | OPRM1KCNH2BCL2CXCR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | OPRM1 4690/4885OPRL1 3672/4885HTR2A 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.